Yes there was an ASX ann some time ago that the naming process was afoot. Typical and for good reason, reputable bio-company only name a drug after a phase two trial and well on there way to FDA registration. I say reputably because it is somewhat cheeky to brand name a drug early as it is misleading in the normative drug culture world of progress. IE it gives the impression the drug is further advanced than is the normal practice. Thus Kazia management will play the conservative normative route, that may be slow but lends its self towards more credible and serious discussions with potentials partners.
"When a drug is approved by the Food and Drug Administration (FDA—the U.S. government agency responsible for ensuring that drugs marketed in the United States are safe and effective), it is given a
